Insmed reported $1.28B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Cytokinetics USD 74.94M 863.28M Jun/2025
DBV Technologies USD 103.21M 103.21M Jun/2025
Dynavax Technologies USD 99.1M 562.24M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Insmed USD 1.28B 881.08M Jun/2025
Novartis USD 6.66B 4.8B Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025